Biocompatibles International plc is a leading company in the field of drug-device combination products. The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products. These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer. Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity. We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.
19/11/10
BTG’s planned takeover of Biocompatibles has received a guarded welcome from the market – though analysts say it will take a while to digest the full implications of the deal. However they all agree there is a definite logic to bringing together the specialist pharmaceuticals projects and pipeline of BTG with the innovative bead technology of Biocompatibles, which is currently being used in cancer but has a number of other alternative applications.
27/08/10
Both Nomura Code and Piper Jaffray upbreat after the growing bio-tech firm posted forecast-beating interim results.
13/05/10
After reporting very good progress for the 2009 full-year in March, the company now announced that revenues in the current year to date are already ahead of board expactations.
18/03/10
After better-than-expected sales growth in the 2009 full year, the drug-eluting beads maker forecasts more growth this year while the Oncology Products Division revs up the pace of product trials.
17/02/10
Diabetes is a chronic and progressive disease, according to Biocompatibles more than 6% world's adult population suffer from diabetes and in the US newly diagnosed diabetes has nearly doubled in the last 10 years.
14/10/09
With market leading position in drug-eluting beads (used in more than 35 countries) and The Sunday Times best companies award for 2009, this small biotech shows some promise.
26/01/09
17/12/10
Biocompatibles liver cancer treatment submitted for marketing approval in Japan19/11/10
Biocompatibles accepts BTG's £177 mln bid29/10/10
New study supports use of Biocompatibles Intl's MoleMate for melanoma diagnosis28/10/10
Biocompatibles in advanced offer talks and full-year sales on track15/10/10
Biocompatibles partner committed to Novabel sales re-start, but timing unsure23/09/10
AstraZeneca and Biocompatibles kick of CM3 trial for Type 2 diabetes23/09/10
Biocompatibles Intl starts diabetes patient treatment under CM3 programme with AstraZeneca21/09/10
Biocompatibles shares lifted by confirmation of preliminary approach10/09/10
Biocompatibles interims confirm consistent profitability - Edison Investment Research07/09/10
Piper Jaffray upgrade Biocompatibles revenue forecasts
10/09/2010
09/09/2010
03/12/2009
11/03/2009
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
